Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069987 | 0.89 | MAOA (0.52) | DGAT1THRBL3MBTL1CA12CA1 | |
| Hydrochloric Acid SCHEMBL4419949 | 0.88 | MAOA (0.51) | DGAT1THRBL3MBTL1CA12CA1 | |
| SCHEMBL13415301 | 0.83 | L3MBTL1 (0.69) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL4422414 | 0.81 | GPR119 (0.67) | DGAT1THRBMAPTLMNATSHR | |
| SCHEMBL7074530 | 0.80 | THRB (0.52) | DGAT1THRBCA12CA1CA2 | |
| SCHEMBL7070001 | 0.80 | THRB (0.63) | DGAT1THRBL3MBTL1CA12CA1 | |
| SCHEMBL7075210 | 0.80 | THRB (0.57) | DGAT1THRBL3MBTL1CA12CA1 | |
| SCHEMBL7074179 | 0.79 | MAPT (0.74) | THRBL3MBTL1MAPTTP53LMNA | |
| SCHEMBL7073990 | 0.79 | THRB (0.56) | DGAT1THRBCA12CA1CA2 | |
| SCHEMBL7071891 | 0.79 | THRB (0.63) | DGAT1THRBCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | HUANG TIEN L | 2010-10-21 | — | — | US | disclosed |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | HUANG TIEN L | 2010-10-21 | — | — | US | disclosed |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | HUANG TIEN L | 2010-10-21 | — | — | US | disclosed |
| WO-2008070831-A2 | BISBENZAMIDINES AND BISBENZAMIDOXIMES FOR THE TREATMENT OF HUMAN AFRICAN TRYPANOSOMIASIS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070831-A2 | BISBENZAMIDINES AND BISBENZAMIDOXIMES FOR THE TREATMENT OF HUMAN AFRICAN TRYPANOSOMIASIS | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | XAVIER UNIVERSITY OF LOUISIANA (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139534-A1 | or sleeping sickness, caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense; lethargy, continous sleep, breakdown of neurological function, coma and death; viricide, antiprotozoa agent; Pentamidine analog; topoisomerases II inhibitor; inhibit synthesis of DNA, RNA by parasites | TOP2A, TOP2B, TOP1 | DGAT1 3838/4885THRB 2372/4885L3MBTL1 16/4885 |
| US-20100267702-A1 | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis | PBRM1, TFB2M, ABAT | DGAT1 1616/4885THRB 771/4885L3MBTL1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.